期刊
FRONTIERS IN PSYCHIATRY
卷 13, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fpsyt.2022.809543
关键词
autism spectrum disorder; regression; amyloid precursor protein; sAPP alpha; biomarkers
类别
资金
- Youth Innovation Team of Future Medical Support Plan of Chongqing Medical University [W0037]
- Guangzhou Key Project Early diagnosis and treatment of autism spectrum disorders [202007030002]
- Guangdong Key Project Development of new tools for diagnosis and treatment of autism [2018B030335001]
This study investigated plasma biomarkers in individuals with regressive autism spectrum disorder (RA) and found significantly elevated levels of sAPPtotal and sAPP alpha, which may serve as potential biomarkers for early identification of autism regression.
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder characterized by social communication difficulties, repetitive behaviors, and parochial interests. Individuals with regressive ASD (RA), a unique subtype, have poor outcomes. Moreover, there are currently no validated blood-based biomarkers for ASD, hindering early diagnosis and treatment. This study was the first to examine plasma levels of total secreted amyloid precursor protein (sAPPtotal), secreted amyloid precursor protein-alpha (sAPP alpha), and secreted amyloid precursor protein-beta (sAPP beta) in children diagnosed with RA (n = 23) and compare them with the levels in age-matched children with non-regressive ASD (NRA) (n = 23) and typically developing (TD) controls (n = 23). We found that sAPPtotal and sAPP alpha levels were significantly higher in children with RA than in children with NRA or in TD controls. In contrast, no difference was observed in sAPP beta levels. In conclusion, increased plasma levels of sAPPtotal and sAPP alpha may be valuable biomarkers for the early identification of ASD regression. Prospective studies will be conducted using a larger sample to further investigate these differences.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据